Hans Paul van der Laan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hans Paul van der Laan has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Albertus Langendijk
Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
10 shared publications - Arjen van der Schaaf
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
7 shared publications Hendrik P. Bijl
Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands
5 shared publicationsRoel J.H.M. Steenbakkers
Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
5 shared publications- Erik. W. Korevaar
Department of Radiotherapy, Universitair Medisch Centrum Groningen, PO Box 30 001, Groningen, 9700 RB, NETHERLANDS
3 shared publications Lisa Van Den Bosch
Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 15 March 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101146
The complication sum score: A Delphi-based approach to summarize treatment related complications for esophageal cancer
- 15 March 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101146
Open AccessThe complication sum score: A Delphi-based approach to summarize treatment related complications for esophageal cancer
- Open Access
- 1 March 2025
- Published by Elsevier in Oral Oncology
- Vol. 163, 107224
Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort
- 1 March 2025
- Published by Elsevier in Oral Oncology
- Vol. 163, 107224
Open AccessEvaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort
- Open Access
- 21 December 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 203, 110698
Risk reduction of radiation-induced aspiration by sparing specific aspiration-related-organs at risk; an in silico feasibility study
- 21 December 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 203, 110698
Open AccessRisk reduction of radiation-induced aspiration by sparing specific aspiration-related-organs at risk; an in silico feasibility study
- Open Access
A Decision Support Tool to Optimize Selection of Head and Neck Cancer Patients for Proton Therapy
Selection of head and neck cancer (HNC) patients for proton therapy (PT) using plan comparison (VMAT vs. IMPT) for each patient is labor-intensive. Our aim was to develop a decision support tool to identify patients with high probability to qualify for PT, at a very early stage (immediately after delineation) to avoid delay in treatment initiation. A total of 151 HNC patients were included, of which 106 (70%) patients qualified for PT. Linear regression models for individual OARs were created to predict the Dmean to the OARs for VMAT and IMPT plans. The predictors were OAR volume percentages overlapping with target volumes. Then, actual and predicted plan comparison decisions were compared. Actual and predicted OAR Dmean (VMAT R2 = 0.953, IMPT R2 = 0.975) and NTCP values (VMAT R2 = 0.986, IMPT R2 = 0.992) were highly correlated. The sensitivity, specificity, PPV and NPV of the decision support tool were 64%, 87%, 92% and 51%, respectively. The expected toxicity reduction with IMPT can be predicted using only the delineation data. The probability of qualifying for PT is >90% when the tool indicates a positive outcome for PT. This tool will contribute significantly to a more effective selection of HNC patients for PT at a much earlier stage, reducing treatment delay.
Open AccessA Decision Support Tool to Optimize Selection of Head and Neck Cancer Patients for Proton Therapy
Selection of head and neck cancer (HNC) patients for proton therapy (PT) using plan comparison (VMAT vs. IMPT) for each patient is labor-intensive. Our aim was to develop a decision support tool to identify patients with high probability to qualify for PT, at a very early stage (immediately after delineation) to avoid delay in treatment initiation. A total of 151 HNC patients were included, of which 106 (70%) patients qualified for PT. Linear regression models for individual OARs were created to predict the Dmean to the OARs for VMAT and IMPT plans. The predictors were OAR volume percentages overlapping with target volumes. Then, actual and predicted plan comparison decisions were compared. Actual and predicted OAR Dmean (VMAT R2 = 0.953, IMPT R2 = 0.975) and NTCP values (VMAT R2 = 0.986, IMPT R2 = 0.992) were highly correlated. The sensitivity, specificity, PPV and NPV of the decision support tool were 64%, 87%, 92% and 51%, respectively. The expected toxicity reduction with IMPT can be predicted using only the delineation data. The probability of qualifying for PT is >90% when the tool indicates a positive outcome for PT. This tool will contribute significantly to a more effective selection of HNC patients for PT at a much earlier stage, reducing treatment delay.
- Open Access
- 1 September 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 162, 85-90
Quality of life and toxicity guided treatment plan optimisation for head and neck cancer
- 1 September 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 162, 85-90
Open AccessQuality of life and toxicity guided treatment plan optimisation for head and neck cancer
- Open Access
- 1 July 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 160, 47-53
Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer
- 1 July 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 160, 47-53
Open AccessImpact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer
- Open Access
- 1 April 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 157, 182-187
Risk of ischaemic cerebrovascular events in head and neck cancer patients is associated with carotid artery radiation dose
- 1 April 2021
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 157, 182-187
Open AccessRisk of ischaemic cerebrovascular events in head and neck cancer patients is associated with carotid artery radiation dose
- Open Access
- 26 September 2019
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 58 (12) , 1775-1782
Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer
Background: The aim of this study was to compare adaptive intensity modulated proton therapy (IMPT) robustness and organ sparing capabilities with that of adaptive volumetric arc photon therapy (VMAT). Material and methods: Eighteen lung cancer patients underwent a planning 4DCT (p4DCT) and 5 weekly repeated 4DCT (r4DCT) scans. Target volumes and organs at risk were manually delineated on the three-dimensional (3D) average scans of the p4DCT (av_p4DCT) and of the r4DCT scans (av_r4DCT). Planning target volume (PTV)-based VMAT plans and internal clinical target volume (ICTV)-based robust IMPT plans were optimized in 3D on the av_p4DCT and re-calculated on the av_r4DCTs. Re-planning on av_r4DCTs was performed when indicated and accumulated doses were evaluated on the av_p4DCT. Results: Adaptive VMAT and IMPT resulted in adequate ICTV coverage on av_r4DCT in all patients and adequate accumulated-dose ICTV coverage on av_p4DCT in 17/18 patients (due to a shrinking target in one patient). More frequent re-planning was needed for IMPT than for VMAT. The average mean heart dose reduction with IMPT compared with VMAT was 4.6 Gy (p = .001) and it was >5 Gy for five patients (6, 7, 8, 15, and 22 Gy). The average mean lung dose reduction was 3.2 Gy (p < .001). Significant reductions in heart and lung V5 Gy were observed with IMPT. Conclusion: Robust-planned IMPT required re-planning more often than VMAT but resulted in similar accumulated ICTV coverage. With IMPT, heart and lung mean dose values and low dose regions were significantly reduced. Substantial cardiac sparing was obtained in a subgroup of five patients (28%).
- 26 September 2019
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 58 (12) , 1775-1782
Open AccessOrgan sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer
Background: The aim of this study was to compare adaptive intensity modulated proton therapy (IMPT) robustness and organ sparing capabilities with that of adaptive volumetric arc photon therapy (VMAT). Material and methods: Eighteen lung cancer patients underwent a planning 4DCT (p4DCT) and 5 weekly repeated 4DCT (r4DCT) scans. Target volumes and organs at risk were manually delineated on the three-dimensional (3D) average scans of the p4DCT (av_p4DCT) and of the r4DCT scans (av_r4DCT). Planning target volume (PTV)-based VMAT plans and internal clinical target volume (ICTV)-based robust IMPT plans were optimized in 3D on the av_p4DCT and re-calculated on the av_r4DCTs. Re-planning on av_r4DCTs was performed when indicated and accumulated doses were evaluated on the av_p4DCT. Results: Adaptive VMAT and IMPT resulted in adequate ICTV coverage on av_r4DCT in all patients and adequate accumulated-dose ICTV coverage on av_p4DCT in 17/18 patients (due to a shrinking target in one patient). More frequent re-planning was needed for IMPT than for VMAT. The average mean heart dose reduction with IMPT compared with VMAT was 4.6 Gy (p = .001) and it was >5 Gy for five patients (6, 7, 8, 15, and 22 Gy). The average mean lung dose reduction was 3.2 Gy (p < .001). Significant reductions in heart and lung V5 Gy were observed with IMPT. Conclusion: Robust-planned IMPT required re-planning more often than VMAT but resulted in similar accumulated ICTV coverage. With IMPT, heart and lung mean dose values and low dose regions were significantly reduced. Substantial cardiac sparing was obtained in a subgroup of five patients (28%).
- Open Access
- 1 April 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115 (1) , 56-62
Acute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia
- 1 April 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115 (1) , 56-62
Open AccessAcute symptoms during the course of head and neck radiotherapy or chemoradiation are strong predictors of late dysphagia
- 1 June 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 107 (3) , 282-287
Swallowing-sparing intensity-modulated radiotherapy for head and neck cancer patients: Treatment planning optimization and clinical introduction
- 1 June 2013
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 107 (3) , 282-287
Swallowing-sparing intensity-modulated radiotherapy for head and neck cancer patients: Treatment planning optimization and clinical introduction